Related Experiment Videos
Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes
1Department of Dermatopathology, University Hospital Sart Tilman, Liège, Belgium.
Clinical and Experimental Dermatology
|November 18, 2003
Summary
Pre-treatment density of dermal dendrocytes (DDs) may impact imiquimod efficacy for basal cell carcinoma (BCC). Higher DDs correlated with successful treatment, suggesting DDs influence imiquimod
Area of Science:
- Immunodermatology
- Oncology
- Dermatopathology
Background:
- Dermal dendrocytes (DDs), identified by factor XIIIa immunoreactivity, are often associated with basal cell carcinomas (BCCs).
- Imiquimod is a topical immune response modifier used in treating skin cancers.
Observation:
- A study treated 12 superficial BCCs with imiquimod over 8 weeks.
- Seven lesions resolved, while five showed residual BCC post-treatment.
Findings:
- Pre-treatment assessment revealed that imiquimod-responsive BCCs had a significantly higher density of surrounding DDs compared to imiquimod-resistant BCCs.
- This suggests a correlation between the peritumoral DD density and the therapeutic outcome of imiquimod treatment.
Implications:
- The pretreatment density of dermal dendrocytes may serve as a predictive biomarker for imiquimod treatment response in superficial BCC.
- Further research could explore modulating DD populations to enhance imiquimod efficacy in skin cancer treatment.